References
- Cheng H, Yu Z, Yan CL, Yang HD, Gao C, Wen HY. Long-term efficacy and low adverse events of methylprednisolone pulses combined to low-dose glucocorticoids for systemic sclerosis: a retrospective clinical study of 10 years’ follow-up. J Inflamm Res. 2022;15:4421–4433. doi:10.2147/JIR.S373387
- Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145–1156. doi:10.1007/s00198-019-04906-x
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849
- Panopoulos ST, Tektonidou MG, Bournia VK, Arida A, Sfikakis PP. Anti-interleukin 6 therapy effect for refractory joint and skin involvement in systemic sclerosis: a real-world, single-center experience. J Rheumatol. 2022;49(1):68–73. doi:10.3899/jrheum.210273
- Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2022;4(8):e546–e555. doi:10.1016/S2665-9913(22)00131-X